Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
FRC
First Republic Bank
FRC
|
+$734M |
| 2 |
Boeing
BA
|
+$493M |
| 3 |
Pfizer
PFE
|
+$478M |
| 4 |
UnitedHealth
UNH
|
+$440M |
| 5 |
Honeywell
HON
|
+$364M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$1.05B |
| 2 |
Advanced Micro Devices
AMD
|
+$447M |
| 3 |
TSMC
TSM
|
+$441M |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$372M |
| 5 |
ExxonMobil
XOM
|
+$321M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.34% |
| 2 | Technology | 16.84% |
| 3 | Consumer Discretionary | 12.66% |
| 4 | Industrials | 10.11% |
| 5 | Consumer Staples | 9.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1976
Ligand Pharmaceuticals
LGND
$5.76B
| $2.19M | ﹤0.01% |
29,800
+5,300
| +22% | +$377K |
|
1977
Schwab Fundamental Emerging Markets Large Company Index ETF
FNDE
$9.73B
| $2.19M | ﹤0.01% |
84,100
-76,500
| -48% | -$1.99M |
|
1978
Pulmonx
LUNG
$68.8M
| $2.18M | ﹤0.01% |
194,845
+176,803
| +980% | +$1.75M |
|
1979
Goosehead Insurance
GSHD
$2.2B
| $2.18M | ﹤0.01% |
+41,700
| New | +$1.81M |
|
|
KZR
1980
DELISTED
Kezar Life Sciences
KZR
| $2.18M | ﹤0.01% |
69,568
+61,258
| +737% | +$3.54M |
|
1981
Vanguard Dividend Appreciation ETF
VIG
$112B
| $2.17M | ﹤0.01% |
14,100
-2,400
| -15% | -$368K |
|
|
SGEN
1982
DELISTED
Seagen Inc. Common Stock
SGEN
| $2.17M | ﹤0.01% |
10,700
-429,913
| -98% | -$69M |
|
1983
Inovio Pharmaceuticals
INO
$55.7M
| $2.17M | ﹤0.01% |
220,025
+5,650
| +3% | +$96.3K |
|
1984
Boston Omaha
BOC
$428M
| $2.16M | ﹤0.01% |
91,200
+59,900
| +191% | +$1.49M |
|
1985
Altisource Portfolio Solutions
ASPS
$63.6M
| $2.16M | ﹤0.01% |
58,603
-11,387
| -16% | -$550K |
|
1986
ARS Pharmaceuticals
SPRY
$509M
| $2.15M | ﹤0.01% |
330,600
+19,600
| +6% | +$151K |
|
1987
Elbit Systems
ESLT
$37.9B
| $2.13M | ﹤0.01% |
12,546
+10,546
| +527% | +$1.8M |
|
|
LBC
1988
DELISTED
Luther Burbank Corporation Common Stock
LBC
| $2.13M | ﹤0.01% |
224,768
-31,900
| -12% | -$354K |
|
|
PNT
1989
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $2.12M | ﹤0.01% |
291,700
+268,000
| +1,131% | +$1.99M |
|
1990
Allogene Therapeutics
ALLO
$649M
| $2.12M | ﹤0.01% |
428,700
-11,400
| -3% | -$73.1K |
|
1991
Helios Technologies
HLIO
$2.57B
| $2.12M | ﹤0.01% |
32,375
+14,600
| +82% | +$950K |
|
1992
Nektar Therapeutics
NKTR
$2.39B
| $2.11M | ﹤0.01% |
200,246
+192,439
| +2,465% | +$5.82M |
|
|
STCN
1993
DELISTED
Steel Connect, Inc. Common Stock
STCN
| $2.11M | ﹤0.01% |
198,081
-5,469
| -3% | -$64.2K |
|
1994
Unisys
UIS
$209M
| $2.1M | ﹤0.01% |
542,633
+414,611
| +324% | +$2M |
|
1995
Global X Robotics & Artificial Intelligence ETF
BOTZ
$3.35B
| $2.1M | ﹤0.01% |
82,500
+58,600
| +245% | +$1.38M |
|
1996
AvePoint
AVPT
$2.76B
| $2.1M | ﹤0.01% |
510,000
+54,800
| +12% | +$247K |
|
|
CVLY
1997
DELISTED
Codorus Valley Bancorp Inc
CVLY
| $2.1M | ﹤0.01% |
101,241
+1,036
| +1% | +$24.6K |
|
|
CIM
1998
Chimera Investment
CIM
$1.04B
| $2.1M | ﹤0.01% |
+123,887
| New | +$2.37M |
|
|
OPTU
1999
Optimum Communications Inc
OPTU
$298M
| $2.09M | ﹤0.01% |
612,200
+443,800
| +264% | +$1.89M |
|
|
STRR
2000
Star Equity Holdings
STRR
$39.9M
| $2.09M | ﹤0.01% |
93,965
-5,000
| -5% | -$122K |
|
Similar funds
Renaissance Technologies's Q1 2023 Portfolio in Review
As of Q1 2023, Renaissance Technologies held 4,600 positions worth $75.4B, up 3.1% from $73.1B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Renaissance Technologies's Q1 2023 filing shows 524 new, 1,665 increased, 1,689 reduced and 668 closed positions. Its largest new stake was Honeywell: 1,937,917 shares worth $349M. The largest sale was Apple, an estimated $1.05B.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, down from 21% a quarter earlier, followed by Technology and Consumer Discretionary.
- Renaissance Technologies's largest Q1 2023 buy was Honeywell: 1,937,917 shares worth $349M.
- Renaissance Technologies added most to First Republic Bank in Q1 2023, an estimated $734M increase.
- Renaissance Technologies's biggest Q1 2023 reduction was Apple, cutting an estimated $1.05B.
- Renaissance Technologies fully exited Advanced Micro Devices in Q1 2023, selling an estimated $447M.
- Renaissance Technologies's ten largest holdings make up 11% of its $75.4B portfolio in Q1 2023.
- Renaissance Technologies opened 524 new positions and closed 668 in Q1 2023.
- Renaissance Technologies's portfolio value rose 3.1% quarter-over-quarter to $75.4B.
Based on Renaissance Technologies's 13F filing for Q1 2023, filed 12 May 2023.